What Howard Lotsof Discovered About Ibogaine in 1962

Howard Lotsof was 19 years old and addicted to heroin when he first took ibogaine in 1962. He came out the other side without withdrawal and without craving. The observation he made that year took six decades to replicate under controlled conditions—and the delay was not because his observation was wrong.

This is not a post about a charismatic figure who found a shortcut. It is about what one person’s observation in 1962 eventually produced, what stood in the way, and what the medicine can and cannot do for the people who come to it now.

What Lotsof observed in 1962 — and why it mattered

Lotsof was not seeking treatment for addiction when he took ibogaine. He was a young man who had been using heroin for several years, looking for a psychedelic experience. What he encountered instead was a 36-hour experience that ended with the physical withdrawal symptoms he had expected to experience simply absent.

This was not a clinical assessment. It was a first-person observation under circumstances that made rigorous verification impossible. But it was specific: not just that the experience was powerful, but that something had happened to the pharmacological relationship between him and opioids. He subsequently administered ibogaine to several of his friends who also had heroin addiction. The majority reported the same—interruption of physical withdrawal, reduction in craving, and in some cases a lasting reorientation toward the pattern that had defined their lives.

The observation was consistent with what Bwiti practitioners in Central Africa had understood about iboga root bark for generations. The medicine was confrontational by design—not healing in the Western therapeutic sense, but disruptive in a way that interrupted patterns conventional treatment could not reach. Lotsof had stumbled into the same encounter from a different direction.

He recognised that what he had observed had significance beyond his own experience. He began documenting it. He started trying to get it studied.

The hard part was not the observation. The hard part was everything that came next.

Patents and the long road through NIDA

In 1985, Lotsof filed his first patent for ibogaine as a treatment for opioid dependence. Over the following decade, he obtained additional patents covering stimulant dependence, alcohol dependence, nicotine, and other substances. The patents were not pharmaceutical-grade intellectual property backed by phase III clinical trials. They were a mechanism for demonstrating that the observation was taken seriously enough to document—and to protect—while the larger work of formal verification was pursued.

By the late 1980s, he had attracted enough attention that the National Institute on Drug Abuse began preliminary engagement with ibogaine research. In the early 1990s, NIDA funded limited laboratory and clinical work that produced results consistent with Lotsof’s original observations: ibogaine appeared to affect the neurological systems involved in opioid addiction in ways that conventional pharmacology had not achieved.

The programme was discontinued. The stated reason was logistical: ibogaine’s cardiac safety profile—specifically, its effect on the QT interval—required on-site medical infrastructure that made outpatient clinical trial design difficult to execute safely. This was a real constraint, not a pretextual one. But the deeper issue was structural. Ibogaine’s Schedule I classification in the United States made it commercially uninteresting to pharmaceutical companies and organizationally difficult for academic researchers to pursue at scale. What NIDA had funded was preliminary enough to be encouraging but not definitive enough to overcome the institutional friction.

Lotsof spent the rest of his life working around those barriers. He supported researchers in the Netherlands, in Panama, and in Canada—jurisdictions where ibogaine’s legal status permitted work that the United States blocked. He helped found the International Coalition for Addict Self-Help and later the Ibogaine Association, organisations that kept the evidence base accumulating even as institutional funding had withdrawn.

He died in January 2010. He had not seen the evidence reach the scale his original observation warranted.

Why the research was delayed — and what that delay cost

The fact that ibogaine research was constrained by scheduling policy for approximately 50 years is a policy failure, not a scientific verdict. The evidence that existed despite the obstacles pointed consistently in the same direction—from Lotsof’s first observations in 1962, through the open-label studies conducted in the Netherlands and Panama during the 1990s and 2000s, to the 2023 Stanford study. The direction was never in doubt. The scale of confirmation was.

The cost of that delay is not possible to calculate precisely. The 30 special operations veterans who participated in the Stanford study had already tried conventional treatment. They had been through programmes. They had received diagnoses and medications. Many of them were sceptical that anything was going to work—and they entered the study with the earned scepticism of people who had already seen conventional approaches fail. The 88% average reduction in PTSD symptoms documented at one month is striking not just because of the number, but because of the population: people for whom the standard of care had already failed.

That result was not a surprise to the researchers who had been working with ibogaine for decades. It confirmed what the smaller-scale evidence had been suggesting since Lotsof first documented his own experience. The scheduling status that constrained that research did not reflect the science. It reflected a political decision made in 1970 that was not revisited for half a century.

The $50 million in clinical trial funding committed through UTMB, UTHealth Houston, Texas A&M University, and Baylor University following the Stanford study represents a belated recognition that the evidence warranted serious investigation. It also represents what was not funded for 50 years. Active clinical trials are now registered for ibogaine across multiple conditions. The policy climate has shifted. The science was always there.

What his work eventually produced

The people who come to ibogaine ceremony now inherit a research lineage that Lotsof spent his adult life building from a single first-person observation. The mechanism his observation pointed toward—a neurological reset of opioid receptors, an increase in GDNF that supports new neural pathways, a sustained metabolite that keeps the window of neuroplasticity open for weeks to months—is now reasonably well characterised in the scientific literature. He did not know any of this in 1962. He knew what he had observed.

The people who arrive at ibogaine ceremony with the strongest results are often the ones who spent years trying everything else first. SSRIs that blunted rather than resolved. Therapy that circled without landing. Abstinence-based programmes that held for months, then didn’t. By the time they arrive, they are not naive about the difficulty of what they are attempting. They have evidence that the other approaches are not enough. That scepticism—earned the hard way—tends to produce people who are genuinely ready to encounter what ibogaine shows them.

This is what Lotsof’s first observation eventually produced: not a shortcut, but a different kind of encounter. One that the evidence now consistently supports.

The Stanford study published in Nature Medicine in February 2023 is the most rigorous confirmation of what he first noticed. It is not perfect—30 participants, no placebo arm, outcomes measured at one month post-treatment. Citing these numbers without those caveats is not honest. But the numbers are compelling enough to stand on their own with the caveats included. A 50% reduction in depression scores is what conventional antidepressant research considers a strong response. The Stanford study documented 87% in a population that had already tried the conventional options.

None of this would exist without the 19-year-old who documented what he experienced in 1962 and spent the rest of his life trying to get it confirmed.

Lotsof never framed his observation as a cure. He framed it as an interruption—a window during which something different was possible. That framing has proven accurate. What happens in that window is entirely dependent on what the person does with it. The medicine shows people what they have been avoiding. The integration that follows determines whether the encounter produces lasting change.

Who Is Not Right for This

Lotsof’s discovery does not make ibogaine appropriate for everyone who comes to it. The contraindications are medical, not philosophical, and they do not bend for compelling personal circumstances.

Absolute contraindications include:

• QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction
• Severe liver or kidney disease
• Active psychosis or schizophrenia spectrum disorder
• Current SSRIs or SNRIs — a supervised physician taper is required first; serotonin syndrome risk is real and potentially fatal
• Methadone — a specific transition protocol is required
• Lithium and certain other psychiatric medications
• Pregnancy

Anyone who has heard about Lotsof’s 1962 observation and concluded that ibogaine is therefore safe without medical screening has missed the point. His observation occurred outside medical supervision. The cardiac safety infrastructure that now surrounds legitimate ibogaine ceremony exists precisely because the pharmacology demands it. Providers who skip cardiac screening—EKG and cardiovascular assessment before every ceremony, without exception—are not honouring Lotsof’s work. They are repeating the conditions under which it could go wrong.

Someone whose primary motivation is accessing the historical significance of ibogaine, or experiencing the medicine for its cultural or spiritual dimensions without addressing a specific presenting condition, is not an appropriate candidate. The medicine is not a pilgrimage. It is a confrontation. People who arrive without one come back from it unchanged.

People in acute psychiatric crisis are not appropriate candidates regardless of the relevance of ibogaine to their condition. The experience amplifies what is present. Entering it in a state of acute instability does not produce stability.

Is This Right for You?

Howard Lotsof spent his adult life trying to get the answer to this question answered properly. The research that now exists—including the Stanford study, the Texas clinical trial programme, and the decades of smaller-scale clinical work conducted outside the United States—gives us a much clearer picture than he had access to in 1962.

The picture is not unlimited. The medicine is not appropriate for everyone who asks for it. But for people who have tried the available conventional options and found them insufficient—people with treatment-resistant depression, trauma, or opioid and stimulant addiction who have already done the work that ibogaine is supposed to follow—the evidence Lotsof spent his life building now justifies taking it seriously.

If you want to understand whether this work is appropriate for you specifically, start with the FAQ. If you have already read it and want to begin a formal intake, the application is where that process starts. Every application receives a personal response within 2–3 business days. If you have questions about what integration looks like after ceremony, that information is there as well.

Lotsof’s first observation was not that ibogaine was easy. It was that it worked. Those are different things.